>

George Yancopoulos - Regeneron Pharmaceuticals President

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>RE</div>
REGN -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  President
Dr. George D. Yancopoulos, M.D., Ph.D., is President and Chief Scientific Officer Regeneron, Director of the Company. Dr. Yancopoulos joined Dr. Schleifer in 1989 as founding scientist of the Company, and together they built and have managed the Company since then. Dr. Yancopoulos is currently President and Chief Scientific Officer, and has served on the board since 2001. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor andor developer of the five FDAapproved drugs the Company has developed, EYLEA Injection, Praluent Injection, Dupixent Injection, ZALTRAP Injection for Intravenous Infusion, and ARCALYST Injection for Subcutaneous Use, as well as of its foundation technologies, including the TRAP technology, VelociGene, and VelocImmune. As one of the few members of the National Academy of Sciences from industry and as an author of a substantial number of scientific publications, Dr. Yancopoulos has a distinguished record of scientific expertise
Age: 58  President Since 2016      
914 847-7000  www.regeneron.com
Yancopoulos also brings to the board his experience in building and managing the Company, his indepth knowledge of the Company?s technologies and research and development programs, and his proven trackrecord for envisioning successful longterm strategic directions and opportunities.

George Yancopoulos Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 13.61 % which means that it generated profit of $13.61 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 18.87 % meaning that it created $18.87 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Jeffrey NeedhamPerrigo Company Plc
2009
Scott JamisonPerrigo Company Plc
2011
Roman TrawickiZoetis
2015
Thomas GraneyVertex Pharmaceuticals Incorpor
2017
Douglas BoothePerrigo Company Plc
2013
Glenn DavidZoetis
2016
Stefan WeiskopfZoetis
2013
Raghav ChariDr Reddys Laboratories Ltd
2013
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Michael PariniVertex Pharmaceuticals Incorpor
2017
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Roxanne LaganoZoetis
2015
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Andrew FentonZoetis
2018
Catherine KnuppZoetis
2012
K RaoDr Reddys Laboratories Ltd
2016
Alejandro BernalZoetis
2015
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
John HendricksonPerrigo Company Plc
2016
Paul SilvaVertex Pharmaceuticals Incorpor
2019

Company Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 8100 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 8,100 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent DirectorView
Joseph Goldstein, Independent DirectorView
Anthony Coles, Independent DirectorView
George Sing, Independent DirectorView
Peter Powchik, Senior Vice President - Clinical DevelopmentView
Jay Markowitz, Senior Vice President - Portfolio ManagementView
Robert Terifay, Sr. VP of CommercialView
Robert Landry, CFO and Sr. VP of Fin.View
Michael Brown, Independent DirectorView
Christine Poon, Independent DirectorView
Neil Stahl, Executive VP of RandDView
Marion McCourt, Senior Vice President and Head of CommercialView
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, DirectorView
Huda Zoghbi, DirectorView
Bonnie Bassler, DirectorView
Joseph LaRosa, Senior Vice President General Counsel, SecretaryView
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product SupplyView
Leonard Schleifer, President CEO, DirectorView
Alfred Gilman, Independent DirectorView
Roy Vagelos, Chairman of the BoardView
Michael Aberman, Vice President - StrategyView
Manisha Narasimhan, IR ContactView
Douglas McCorkle, Vice President Controller, Assistant TreasurerView
Marc TessierLavigne, Independent DirectorView
Christopher Fenimore, Vice President ControllerView
Arthur Ryan, Independent DirectorView

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

GM   
Purchased over 100 shares of
a day ago
Traded for 30.71
ECA   
Purchased over 500 shares of
a day ago
Traded for 3.54
GM   
Purchased over 100 shares of
a day ago
Traded for 30.71
WD   
Purchased over 40 shares of
a day ago
Traded for 66.38
DD   
Purchased over 70 shares of
a day ago
Traded for 43.18
Additionally, take a look at Your Equity Center. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.